

N-α-Fmoc-lysine (2)

N-α-Fmoc-Lys(N-ε-tBoc) (1)

Fig. 1a





Fig. 1b



N-ε-biotinyl lysine

N-α-Fmoc-Lys(N-ε-biotin)

Fig. 1c

Fig. 2a






Fig. 2b



sample 8320



sample 8242





Fig. 3a-1

sample 8243



sample 8318





Fig. 3a-2

sample 8320



sample 8326





Fig. 3b-1

sample 8242



sample 8243





Fig. 3b-2

sample 8243



sample 8318





Fig. 3c-1

sample 8326



sample 8242





Fig. 3c-2

HCV peptide II-BIO



HCV peptide XI-BIO




Fig. 4a

HCV peptide XVI-BIO






Fig. 4b

Fig. 5a



N-terminally biotinylated
TM peptide

Fig. 5b



C-terminally biotinylated
TM peptide

Fig. 6a-1





Fig. 6a-2





Fig. 6a-3





Fig. 6a-4





Fig. 6a-5








Fig. 6b-1



Sample 8332



Sample 8339




Fig. 6b-3





Fig. 6b-4





Fig. 6b-5





Fig. 6c-1





Fig. 6c-2





Fig. 6c-3






Fig. 6c-4

Sample 8339



Sample 8339 (continued)




Fig. 6c-5





Fig. 6c-6





Fig. 6c-7




Fig. 6c-8




Fig. 6c-9





Fig. 6c-10





Fig. 7a-1

| | | |
|-------------|------------------------|-----------------|
| Peptide I | MSTIPKPQRKTKRNTNRRPQ | (SEQ ID NO:453) |
| peptide II | PQRKTKRNTNRRRPQDVKFPG | (SEQ ID NO:454) |
| peptide III | RNTNRRRPQDVKFPPGGGQIVG | (SEQ ID NO:455) |

| Peptide I | Peptide II | Peptide III |
|-----------------|------------------|------------------|
| (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) |
| (178) MSTIPKPQR | (184) PQRKTKRNT | (190) RNTNRRPQD |
| (179) STIPKPQRK | (185) QRKTKRNTN | (191) NTNRRRPQDV |
| (180) TIPKPQRKT | (186) RKTNRNTNR | (192) TNRRRPQDVK |
| (181) IPKPQRKTK | (187) KTKRNTNRR | (193) NRRPQDVKF |
| (182) PKPQRKTKR | (188) TKRNTNRRP | (194) RRPQDVKFPP |
| (183) KPQRKTKRN | (189) KRNTNRRPQ | (195) RPQDVKFPPG |
| (184) PQRKTKRNT | (190) RNTNRRRPQD | (196) PQDVKFPPGG |
| (185) QRKTKRNTN | (191) NTNRRRPQDV | (197) QDVKFPPGGG |
| (186) RKTNRNTNR | (192) TNRRRPQDVK | (198) DVKFPPGGGQ |
| (187) KTKRNTNRR | (193) NRRPQDVKF | (199) VKFPPGGGQI |
| (188) TKRNTNRRP | (194) RRPQDVKFPP | (200) KFPGGGQIV |
| (189) KRNTNRRPQ | (195) RPQDVKFPPG | (201) FPPGGGQIVG |

Fig. 7a-2

Core 5 PGGGQIVGGVYLLPRRGPRL (SEQ ID NO:456)
 Peptide IV LPRRGPRLGVRATRKTSERS (SEQ ID NO:457)
 Peptide V (SEQ ID NO:458) TRKTSERSQPRGRRQPIPKV
 Peptide VI (SEQ ID NO:459) RRQPIPKVRRPEGRTWAQPG

| Core 5 | Peptide IV | Peptide V | Peptides VI |
|-----------------|------------------|--------------|------------------|
| (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) |
| (202) PGGGQIVGG | (214) LPRRGPRLG | TRKTSERSQ | (238) RRQPIPKVR |
| (203) GGGQIVGGV | (215) PRRGPRLGV | RKTSERSQP | (239) RQPIPKVRR |
| (204) GGQIVGGVY | (216) RRGPRRLGVR | KTSEERSQPR | (240) QPIPKVRRP |
| (205) GQIVGGVYL | (217) RGPRLGVRA | TSEERSQPRG | (241) PIPKVVRRPE |
| (206) QIVGGVYLL | (218) GPRLGVRA | SERSQPRGR | (242) IPKVVRRPEG |
| (207) IVGGVYLLP | (219) PRLGVRA | ERSQPRGR | (243) PKVVRRPEG |
| (208) VGGVYLLPR | (220) RLGVRA | RSQPRGR | (244) KVVRRPEG |
| (209) GGVYLLPRR | (221) LGVRA | SQPRGR | (245) VRRPEG |
| (210) GYLLPRRG | (222) GVRATRK | QPRGRQPI | (246) RRPEGRTWA |
| (211) VYLLPRRG | (223) VRATRK | PRGRQPI | (247) RPEGRTWAQ |
| (212) YLLPRRG | (224) RATRK | RGRQPIPK | (248) PEGRTWAQ |
| (213) LLPRRG | (225) ATRK | GRRQPIPKV | (249) EGRTWAQPG |

Fig. 7a-3




Fig. 76-1

HCV1 LSGKPAIIPDREVLRYEFDE (SEQ ID NO:460)
HCV2 IIPDREVLRYEFDEMEECSSQ (SEQ ID NO:460)
HCV3 VLYREFDEMEECSSQHLPLYIE (SEQ ID NO:462)
HCV4 DEMEECSQHLPLYIEQGMMLA (SEQ ID NO:463)
HCV5 SQHLPLYIEQGMMLAEQFKQK (SEQ ID NO:464)
HCV6 IEQGMMLAEQFKQKALGLLO (SEQ ID NO:465)

| <u>HCV1</u> | <u>HCV2</u> | <u>HCV3</u> | <u>HCV4</u> | <u>HCV5</u> | <u>HCV6</u> |
|-----------------|---------------|---------------|----------------|---------------|--------------|
| (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) |
| (258) LSGKPAIIP | 264IIPDREVLY | 270VLYREFDEM | 276 DEMEECSQH | 282SQHLPYIEQ | 288IEQGMMLAE |
| (259) SGKPAIIPD | 265IIPDREVLYR | 271LYREFDEME | 277 EMEEC SQHL | 283QHLPYIEQG | 289EQGMMLAEQ |
| (260) GKPAIIPDR | 266PDREVLYRE | 272YREFDEMEEE | 278 MEECSQHLP | 284HLPYIEQGM | 290QGMMLAEQF |
| (261) KPAIIPDRE | 267DREVLYREF | 273REFDEMEEC | 279 EEC SQHLPY | 285LPYIEQGM | 291GMMLAEQFK |
| (262) PAIIPDREV | 268 REVLYREFD | 274EFDEMEEC | 280 ECSQHLPYI | 286PYIEQGMML | 292MMLAEQFKQ |
| (263) AIIPDREVL | 269 EVLYREFDE | 275FDEMEEC | 281 CSQHLPYIE | 287YIEQGMMLA | 293MLAEQFKQK |
| (264) IIPDREVLY | 270 VLYREFDEM | 276DEMEEC SQH | 282 SQHLPYIEQ | 288 IEQGMMLAE | 294LAEQFKQKA |
| (265) IPDREVLYR | 271 LYREFDEME | 277EMEEC SQHL | 283 QHLPYIEQG | 289EQGMMLAEQ | 295AEQFKQKAL |
| (266) PDREVLYRE | 272 YREFDEME | 278MEEC SQHLP | 284 HLPYIEQGM | 290QGMMLAEQF | 296EQFKQKALG |
| (267) DREVLYREF | 273 REFDEMEEC | 279EECSQHLPY | 285 LPYIEQGM | 291GMMLAEQFK | 297QFKQKALGL |
| (268) REVLYREFD | 274 EFDEMEEC | 280ECSQHLPYI | 286 PYIEQGMML | 292MMLAEQFKQ | 298FKQKALGLL |
| (269) EVLYREFDE | 275 FDEMEEC | 281CSQHLPYIE | 287 YIEQGMMLA | 293MLAEQFKQK | 299KQKALGLLO |

Fig. 7b-2

| | |
|------|--------------------------------------|
| HCV7 | LAEQFKQKALGLLQTASRQA (SEQ ID NO:466) |
| HCV8 | QKALGLLQTASRQAEVIAPA (SEQ ID NO:467) |
| HCV9 | LQTASRQAEVIAPAVQTNWQ (SEQ ID NO:468) |

| <u>HCV7</u> | <u>HCV8</u> | <u>HCV9</u> |
|-----------------------|-----------------|--------------|
| (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) |
| (294) LAEQFKQKA (300) | QKALGLLQT (306) | LQTASRQAE |
| (295) AEQFKQKAL (301) | KALGLLQTA (307) | QTASRQAEV |
| (296) EQFKQKALG (302) | ALGLLQTAS (308) | TASRQAEVI |
| (297) QFKQKALGL (303) | LGLLQTASR (309) | ASRQAEVIA |
| (298) FKQKALGLL (304) | GLLQTASRQ (310) | SRQAEVIAP |
| (299) KQKALGLLQ (305) | LLQTASRQA (311) | RQAEVIAPA |
| (300) QKALGLLQT (306) | LQTASRQAE (312) | QAEVIAPAV |
| (301) KALGLLQTA (307) | QTASRQAEV (313) | AEVIAPAVQ |
| (302) ALGLLQTAS (308) | TASRQAEVI (314) | EVIAPAVQT |
| (303) LGLLQTASR (309) | ASRQAEVIA (315) | VIAPAVQTN |
| (304) GLLQTASRQ (310) | SRQAEVIAP (316) | IAPAVQTNW |
| (305) LLQTASRQA (311) | RQAEVIAPA (317) | APAVQTNWQ |

Fig. 7b-3




Fig. 7c-1

NS5-21 GNITRYESENKVVILDSFDP (SEQ ID NO:469)
 NS5-23 VILDSFDPLVAEEDEREISV (SEQ ID NO:470)
 NS5-25 EDEREISVPAEILRKSRFFA (SEQ ID NO:471)
 NS5-27 (SEQ ID NO:472) LRKSRFFAQLPVWARPDYN
 NS5-29 (SEQ ID NO:473) VWARPDYNPPLVETWKKPDY

| | <u>NS5-21</u> | <u>NS5-23</u> | <u>NS5-25</u> | <u>NS5-27</u> | <u>NS5-29</u> |
|------------|---------------|----------------|---------------|---------------|---------------|
| SEQ ID NO: | SEQ ID NO: | SEQ ID NO: | SEQ ID NO: | SEQ ID NO: | SEQ ID NO: |
| 318 | GNITRYESE 330 | VILDSFDPL 342 | EDEREISVP 354 | LRKSRFFAQ 366 | VWARPDYNP |
| 319 | NITRYESEN 331 | ILDSFDPLV 343 | DEREISVPA 355 | RKSRFFAQ 367 | WARPDYNPP |
| 320 | ITRYESENK 332 | LDSFDPLVA 344 | EREISVPAE 356 | KSRFFAQAL 368 | ARPDYNPPL |
| 321 | TRYESENKV 333 | DSFDPLVAE 345 | REISVPAEI 357 | SRRFAQALP 369 | RPDYNPPLV |
| 322 | RYESENKVV 334 | SFDPLVAEE 346 | EISVPAEIL 358 | RRFAQALPV 370 | PDYNPPLVE |
| 323 | YESENKVI 335 | FDPLVAEED 347 | ISVPAEILR 359 | RFAQALPVW 371 | DYNPPLVET |
| 324 | ESENKVVIL 336 | DPLVAEED 348 | SVPAEILRK 360 | FAQALPVA 372 | YNPPLVETW |
| 325 | SENKVVILD 337 | PLVAEEDER 349 | VPAEILRKS 361 | AQALPVWAR 373 | NPPLVETWK |
| 326 | ENKVVILDS 338 | LVAEEDERE 350 | PAEILRKSR 362 | QALPVWARP 374 | PPLVETWKK |
| 327 | NKVVILDSF 339 | VAEEDEREI 351 | AEILRKSR 363 | ALPVWARPD 375 | PLVETWKKP |
| 328 | KVVILDSFD 340 | AEEDEREIS 352 | EILRKSRFF 364 | LPVWARPDY 376 | LVETWKKPD |
| 329 | VVILDSFDP 341 | EEEDEREISV 353 | ILRKSRFFA 365 | PVWARPDYN 377 | VETWKKPDY |

Fig. 7c-2

NS5-31
NS5-33

ETWKKPDYEPPVHGCPLPP (SEQ ID NO:474)
(SEQ ID NO:475) VHGCPLEPPKSPPPPPRKK

| <u>NS5-31</u> | | <u>NS5-33</u> | |
|---------------|--------------|---------------|--------------|
| (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) | (SEQ ID NO:) |
| 378 | ETWKKPDYE | 390 | VHGCPLEPPK |
| 379 | TWKKPDYEP | 391 | HGCPLPPKS |
| 380 | WKKPDYEPP | 392 | GCPLPPKSP |
| 381 | KKPDYEPPV | 393 | CPLPPKSPP |
| 382 | KPDYEPPVV | 394 | PLPPKSPPV |
| 383 | PDYEPPVVH | 395 | LPPPKSPPV |
| 384 | DYEPPVVHG | 396 | PPKSPPVP |
| 385 | YEPVVHGC | 397 | PPKSPPVPP |
| 386 | EPPVVHGC | 398 | PKSPPVPPP |
| 387 | PPVVHGCPL | 399 | KSPPVPPPR |
| 388 | PVVHGCPLP | 400 | SPPVPPPRK |
| 389 | VVHGCPLPP | 401 | PPVPPPRKK |

Fig. 7c-3




Fig. 7c-4





Fig. 8



- a: High intensity control
- b: Low intensity control
- c: Medium intensity control
- d: Peptide XXg-1, unbiotinylated
- e: Peptide XXg-2, unbiotinylated
- f: Biotinylated peptide XXg-1: streptavidin complex
- g: Biotinylated peptide XXg-2: streptavidin complex


[illegible]

Fig. 10




Fig. 11

| Peptide | Sequence |
|---------|--------------------------------------|
| NS4-a | GALVAFKIMSGEVPSTEDLV (SEQ ID NO:445) |
| NS4-b | VPSTEDLVNLLPAILSPGAL (SEQ ID NO:446) |
| NS4-c | AILSPGALVGVVCAAILRR (SEQ ID NO:447) |
| NS4-d | (SEQ ID NO:448) VCAAILRRHVGPGEVAVQWM |
| NS4-e | (SEQ ID NO:449) GEGAVQWMNRLIAFASRGNH |

Fig. 12

| (SEQ ID NO:) | Amino Acid Sequence |
|--------------------|--|
| Epi-152 (450) | Bio- G G - I P D R E V L Y R G G K K P D Y E P P V G G R R P Q D V K F P <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="border: 1px solid black; padding: 2px;">NS4 epitope 1</div> <div style="border: 1px solid black; padding: 2px;">NS5 epitope 5</div> <div style="border: 1px solid black; padding: 2px;">Core epitope 2</div> </div> |
| Epi-33B3A (451) | Bio- G G - W A R P D Y N P P G G Q F K Q K A L G L G S G V Y L L P R R G <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="border: 1px solid black; padding: 2px;">NS5 epitope 3</div> <div style="border: 1px solid black; padding: 2px;">NS4 epitope 3B</div> <div style="border: 1px solid black; padding: 2px;">Core epitope 3A</div> </div> |
| Epi-4B2A6 (452) | Bio- G G - R G R R Q P I P K G G S Q H L P Y I E Q S G P V V H G C P L P <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="border: 1px solid black; padding: 2px;">Core epitope 4B</div> <div style="border: 1px solid black; padding: 2px;">NS4 epitope 2A</div> <div style="border: 1px solid black; padding: 2px;">NS5 epitope 6</div> </div> |


[illegible]

Fig. 14c




Fig. 14d




Fig. 15




Fig. 16A





Fig. 16B

Cleavage and side-chain deprotection



Oxidation and dimerization






Fig. 17A



RABBIT 325, 326: XXb-2-MAP
RABBIT 327, 328: XXg-2-MAP

Fig. 17B



RABBIT 325, 326: XXb-2-MAP
RABBIT 327, 328: XXg-2-MAP

BBI ANTI-HTLV I/II MIXED TITER PERFORMANCE PANEL PRP302




Fig. 18

BLOOD DONOR SERA